Pfizer and Teva's settlement puts generic Celebrex on the market by December.
Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.
The announcement will create the fifth largest generics drug maker, reports Reuters.
At a hearing today, Public Citizen and the generics industry are sounding off on an FDA proposal that would allow generics firms to update labels, regardless of whether the brand has or hasn't.
The regulator disputes findings that generic heart drugs made abroad were contaminated.
GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.
The drugmaker's CEO tells Reuters it is in a good position to weather troubles in India's generics industry.
The drugmaker's outreach efforts involve switching patients to the latest—and patented—Copaxone formulation.
The White House's proposed FY 2015 budget gives an additional 1% to the FDA.
The regulator is allowing generic makers room on the OTC contraceptive shelf.
Critics say the FDA is not doing enough to ensure generics quality and that communications between industry and the regulator need to improve.
The drugmaker says the voluntary measure was out of an abundance of caution.
The regulator kicked off a $20-million generics testing project in September.
The drugmakers admitted no wrongdoing, but are paying the state $300,000 over an agreement not to challenge generics filings.
The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.
Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren't drastic enough to make it necessary, experts argued at an FTC workshop.
FDA found workers were manipulating test data.
Purdue Pharma says it will appeal.
The generics giant is splitting the business into four separate units with a newly appointed leader running each.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
The company's guidance aligns with expectations that 2014 will be a nail-biter.
The generics maker says an adalimumab biosimilar would anchor its immunology portfolio.
The company released two financial scenarios. The key is generic Copaxone.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
ProPublica's deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare's budget.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
The proposed change would allow generics makers to update labels even if branded drugmakers do not, possibly opening up generics to new liability issues.
Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.